Phase 2 open-label study of weekly docosahexaenoic acid-paclitaxel in cutaneous and mucosal metastatic melanoma patients

Melanoma Research

Volumn 19, Issue 4, 2009, Pages 238-242

  Homsi, Jade ^a   Bedikian, Agop Y ^a   Kim, Kevin B ^a   Papadopoulos, Nicholas E ^a   Hwu, Wen Jen ^a   Mahoney, Sandy L ^a   Hwu, Patrick ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Cancer; Chemotherapy; Melanoma; Paclitaxel; Patient

Indexed keywords

DOCOSAHEXAENOIC ACID; PACLITAXEL; TAXOPREXIN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; CELLULITIS; CLINICAL ARTICLE; CLINICAL TRIAL; CONFUSION; CONSTIPATION; COUGHING; DIARRHEA; DISEASE COURSE; DISEASE DURATION; DIZZINESS; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG SCREENING; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; EDEMA; FATIGUE; FEMALE; HEADACHE; HUMAN; HYPERSENSITIVITY; INTESTINE OBSTRUCTION; MALE; MELANOMA; MUCOSA; MULTIPLE CYCLE TREATMENT; MUSCULOSKELETAL PAIN; MYALGIA; NAUSEA; NEUROPATHY; NEUTROPENIA; OPEN STUDY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RASH; SKIN METASTASIS; STOMATITIS; SURVIVAL TIME; THORAX PAIN; TREATMENT DURATION; TREATMENT REFUSAL; VISUAL DISORDER; VOMITING;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; DIARRHEA; EXANTHEMA; FATIGUE; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; KAPLAN-MEIER ESTIMATE; MALE; MELANOMA; MIDDLE AGED; NEUTROPENIA; PACLITAXEL; PAIN; SKIN NEOPLASMS; SURVIVAL RATE; TUMOR BURDEN;

EID: 68949136812     PISSN: 09608931     EISSN: None     Source Type: Journal    
DOI: 10.1097/CMR.0b013e32832a1e2f     Document Type: Article

References (29)

1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ, et al. Cancer statistics 2007. CA Cancer J Clin 2007; 57:43-66.
2. Middleton MR, Grob JJ, Aaronson N, Fierlbeck G, Tilgen W, Seiter S, et al. Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. J Clin Oncol 2000; 18:158-166. Erratum in: J Clin Oncol 2000; 18:2351.
3. Agarwala SS, Glaspy J, O'Day SJ, Mitchell M, Gutheil J, Whitman E, et al. Results from a randomized phase III study comparing combined treatment with histamine dihydrochloride plus interleukin-2 versus interleukin-2 alone in patients with metastatic melanoma. J Clin Oncol 2002; 20:125-133.
4. Bedikian AY, Millward M, Pehamberger H, Conry R, Gore M, Trefzer U, et al. Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: the Oblimersen Melanoma Study Group. J Clin Oncol 2006; 24:4738-4745.
5. Atkins MB, Lotze MT, Dutcher JP, Fisher RI, Weiss G, Margolin K, et al. High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J Clin Oncol 1999; 17:2105-2116.
6. Einzig AI, Hochster H, Wiernik PH, Trump DL, Dutcher JP, Garowski E, et al. A phase II study of taxol in patients with malignant melanoma. Invest New Drugs 1991; 9:59-64.
7. Bedikian AY, Weiss GR, Legha SS, Burris HA Jr, Eckardt JR, Jenkins J, et al. Phase II trial of docetaxel in patients with advanced cutaneous malignant melanoma previously untreated with chemotherapy. J Clin Oncol 1995; 13:2895-2899.
8. Bradley MO, Webb NL, Anthony FH, Devanesan P, Witman PA, Hemamalini S, et al. Tumor targeting by covalent conjugation of a natural fatty acid to paclitaxel. Clin Cancer Res 2001; 7:3229-3238.
9. Bradley MO, Swindell CS, Anthony FH, Witman PA, Devanesan P, Webb NL, et al. Tumor targeting by conjugation of DHA to paclitaxel. J Control Release 2001; 74:233-236.
10. Wolff AC, Donehower RC, Carducci MK, Carducci MA, Brahmer JR, Zabelina Y, et al. Phase I study of docosahexaenoic acid-paclitaxel: a taxane-fatty acid conjugate with a unique pharmacology and toxicity profile. Clin Cancer Res 2003; 9:3589-3597.
11. Fracasso PM, Picus J, Wildi JD, Goodner SA, Creekmore AN, Gao F, et al. Phase 1 and pharmacokinetic study of weekly docosahexaenoic acid-paclitaxel, taxoprexin, in resistant solid tumor malignancies. Cancer Chemother Pharmacol 2009; 63:451-458. [Epub ahead of print]
12. Green MC, Buzdar AU, Smith T, Ibrahim NK, Valero V, Rosales MF, et al. Weekly paclitaxel improves pathologic complete remission in operable breast cancer when compared with paclitaxel once every 3 weeks. J Clin Oncol 2005; 23:5983-5992.
13. Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, Carbone PP. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982; 5:649-655.
14. Fleming TR. One-sample multiple testing procedure for phase II clinical trials. Biometrics 1982; 38:143-151.
15. Wani MC, Taylor HL, Wall ME, Coggon P, McPhail AT. Plant antitumor agents. VI. The isolation and structure of taxol, a novel antileukemic and antitumor agent from Taxus brevifolia. J Am Chem Soc 1971; 93:2325-2327.
16. Rowinsky EK, Donehower RC. Paclitaxel (taxol). N EnglJ Med 1995; 332:1004-1014.
17. Wiernik PH, Schwartz EL, Einzig A, Straumann JJ, Lipton RB, Dutcher JP. Phase I trial of taxol given as a 24-h infusion every 21 days: responses observed in metastatic melanoma. J Clin Oncol 1987; 5:1232-1239.
18. Hodi FS, Soiffer RJ, Clark J, Finkelstein DM, Haluska FG. Phase II study of paclitaxel and carboplatin for malignant melanoma. Am J Clin Oncol 2002; 25:283-286.
19. Zonder JA, LoRosso P, Heilbrun L, Flaherty LE. Phase II trial of weekly paclitaxel as 2nd line treatment of metastatic malignant melanoma [Abstract]. Am Soc Clin Oncol 2000.
20. Bedikian AY, Plager C, Papadopoulos N, Eton O, Ellerhorst J, Smith T. Phase II evaluation of paclitaxel by short intravenous infusion in metastatic melanoma. Melanoma Res 2004; 14:63-66.
21. Zimpfer-Rechner C, Hofmann U, Figl R, Becker JC, Trefzer U, Keller I, et al. Randomized phase II study of weekly paclitaxel versus paclitaxel and carboplatin as second-line therapy in disseminated melanoma: a multicentre trial of the Dermatologic Co-operative Oncology Group (DeCOG). Melanoma Res 2003; 13:531-536.
22. Legha SS, Ring S, Papadopoulos N, Raber M, Benjamin RS. A phase II trial of taxol in metastatic melanoma. Cancer 1990; 65:2478-2481.
23. Walker L, Schalch H, King DM, Dietrich L, Eastman M, Kwak M, et al. Phase II trial of weekly paclitaxel in patients with advanced melanoma. Melanoma Res 2005; 15:453-459.
24. Feun LG, Savaraj N, Hurley J, Marini A. Phase II trial of paclitaxel and dacarbazine with filgrastim administration in advanced malignant melanoma. Cancer Invest 2002; 20:357-361.
25. González-Cao M, Viteri S, D?́az-Lagares A, González A, Redondo P, Nieto Y, et al. Preliminary results of the combination of bevacizumab and weekly paclitaxel in advanced melanoma. Oncology 2008; 74:12-16.
26. Smith RE, Brown AM, Mamounas EP, Anderson SJ, Lembersky BC, Atkins JH, et al. Randomized trial of 3-h versus 24-h infusion of high-dose paclitaxel in patients with metastatic or locally advanced breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-26. J Clin Oncol 1999; 17:3403-3411.
27. Fennelly D, Aghajanian C, Shapiro F, O'Flaherty C, McKenzie M, O'Connor C, et al. Phase I and pharmacologic study of paclitaxel administered weekly in patients with relapsed ovarian cancer. J Clin Oncol 1997; 15:187-192.
28. Jones RJ, Hawkins RE, Eatock MM, Ferry DR, Eskens FA, Wilke H, et al. A phase II open-label study of DHA-paclitaxel (Taxoprexin) by 2-h intravenous infusion in previously untreated patients with locally advanced or metastatic gastric or oesophageal adenocarcinoma. Cancer Chemother Pharmacol 2008; 61:435-441.
29. Payne M, Ellis P, Dunlop D, Ranson M, Danson S, Schacter L, et al. DHA-paclitaxel (taxoprexin) as first-line treatment in patients with stage 1MB or IV non-small cell lung cancer: report of a phase II open-label multicenter trial. J Thorac Oncol 2006; 1:984-990.